-
公开(公告)号：US20130012561A1
公开(公告)日：2013-01-10
申请号：US13613467
申请日：2012-09-13
Applicant: Nicholas D. SMITH , Mehmet Kahraman , Steven P. Govek , Johnny Y. Nagasawa , Andiliy G. Lai , Jackaline D. Julien , Celine Bonnefous
Inventor： Nicholas D. SMITH , Mehmet Kahraman , Steven P. Govek , Johnny Y. Nagasawa , Andiliy G. Lai , Jackaline D. Julien , Celine Bonnefous
IPC: A61K31/416 , A61P35/00
CPC classification number: C07D231/56 , A61K31/416 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K31/7105 , C07C215/10 , C07D209/08 , C07D215/227 , C07D217/24 , C07D249/18 , C07D265/18 , C07D277/68 , C07D279/16 , C07D401/10 , C07D401/12 , C07D403/10 , C07D409/10 , C07D413/10 , C07D417/10 , C07D471/04 , C07D495/04
Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
公开(公告)号：US20080139558A1
公开(公告)日：2008-06-12
申请号：US11678572
申请日：2007-02-23
Applicant: Nicholas D. Smith , Jeffrey R. Roppe , Celine Bonnefous , Joseph E. Payne , Hui Zhuang , Xiaohong Chen , Andrew K. Lindstrom , Sergio G. Duron , Christian A. Hassig , Stewart A. Noble
Inventor： Nicholas D. Smith , Jeffrey R. Roppe , Celine Bonnefous , Joseph E. Payne , Hui Zhuang , Xiaohong Chen , Andrew K. Lindstrom , Sergio G. Duron , Christian A. Hassig , Stewart A. Noble
IPC: A61K31/47 , A61K31/5377 , A61P11/06 , A61P17/04 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/14 , A61P29/02 , A61P3/10 , A61P31/00 , A61P31/12 , A61P31/22 , A61P37/00 , A61P37/08 , A61P9/10 , C07D215/227 , C07D295/00 , C07D471/04
CPC classification number: C07D405/12 , A61K31/4704 , A61K31/4709 , C07D215/227 , C07D401/06 , C07D401/12 , C07D409/12
Abstract: The present invention relates to novel quinolones of Formula I that inhibit inducible NOS synthase together with methods of synthesizing and using the compounds including methods for inhibiting or modulating nitric oxide synthesis and/or lowering nitric oxide levels in a patient by administering the compounds for the treatment of disease.
Abstract translation: 本发明涉及抑制诱导型NOS合酶的新型喹诺酮，以及通过给予治疗化合物来合成和使用包括抑制或调节一氧化氮合成和/或降低一氧化氮水平的方法的化合物的方法 的疾病
-
公开(公告)号：US20050065340A1
公开(公告)日：2005-03-24
申请号：US10497452
申请日：2002-11-26
Applicant: Jeannie Arruda , Celine Bonnefous , Brian Campbell , Rowena Cube , Benito Munoz , Brian Stearns , Jean-Michel Vernier , Bowei Wang , Xiumin Zhao
Inventor： Jeannie Arruda , Celine Bonnefous , Brian Campbell , Rowena Cube , Benito Munoz , Brian Stearns , Jean-Michel Vernier , Bowei Wang , Xiumin Zhao
IPC: C07D263/56 , A61K31/422 , A61K31/423 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/506 , A61K31/5377 , A61K45/00 , A61P25/00 , A61P25/04 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P25/34 , A61P25/36 , A61P29/00 , A61P43/00 , C07D263/57 , C07D413/10 , C07D498/04 , C07D521/00 , C07D471/02 , C07D413/02 , C07D417/02 , C07D43/02
CPC classification number: C07D263/57 , C07D231/12 , C07D233/56 , C07D249/08 , C07D413/10
Abstract: Phenyl compounds substituted at the 1-position with a fused bicyclo moeity formed from a five-membered heterocycle fused to a six-membered carbocycle, to a six-membered aryl, or to a six-membered hetaryl, and further optionally substituted at 2 the 3,4 positions, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.
Abstract translation: 苯基化合物在1位上被一个稠合的双环形成，由与六元碳环稠合的五元杂环，六元芳基或六元杂芳基形成，并进一步任选地在2位上被取代 3,4位是用于治疗精神病和情绪障碍（例如精神分裂症，焦虑，抑郁和恐慌）以及治疗疼痛和其他疾病的mGluR5调节剂。
-
公开(公告)号：US20080312286A1
公开(公告)日：2008-12-18
申请号：US11658490
申请日：2005-07-26
Applicant: Anthony B. Pinkerton , Jean-Michel Vernier , Rowena Cube , John Hutchinson , Celine Bonnefous , Theodore Kamenecka
Inventor： Anthony B. Pinkerton , Jean-Michel Vernier , Rowena Cube , John Hutchinson , Celine Bonnefous , Theodore Kamenecka
IPC: C07D257/04 , A61K31/41 , C07C307/02 , A61K31/18 , C07C233/02 , A61K31/454 , C07D401/02 , A61K31/192 , C07C65/00 , C07D213/80 , A61K31/44 , A61K31/343 , C07D307/78 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/08
CPC classification number: C07C233/91 , C07C59/90 , C07C65/40 , C07C311/51 , C07C2601/08 , C07C2602/08 , C07D257/04 , C07D307/79 , C07D401/04
Abstract: The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
Abstract translation: 本发明涉及作为代谢型谷氨酸受体的增强剂（包括mGluR2受体）的化合物，其可用于治疗或预防与谷氨酸能力障碍相关的神经和精神病学障碍以及其中涉及代谢型谷氨酸受体的疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及代谢型谷氨酸受体的疾病中的用途。
-
5.发明申请公开(公告)号：US20080194681A1
公开(公告)日：2008-08-14
申请号：US11792624
申请日：2005-12-09
Applicant: James Malecha , Stewart Noble , Christian Hassig , Paul Wash , Brandon Wiley , Charles Lawrence , Timothy Hoffman , Celine Bonnefous , NIcholas Smith
Inventor： James Malecha , Stewart Noble , Christian Hassig , Paul Wash , Brandon Wiley , Charles Lawrence , Timothy Hoffman , Celine Bonnefous , NIcholas Smith
IPC: A61K31/265 , C07C327/32 , A61P9/00 , A61P7/06 , A61P35/00 , A61P35/04
CPC classification number: C07D213/74 , C07C327/22 , C07C327/28 , C07C327/30 , C07C327/32 , C07D213/32 , C07D213/70 , C07D215/36 , C07D215/38 , C07D231/38 , C07D241/44 , C07D295/192 , C07D295/26 , C07D319/18
Abstract: Disclosed herein are carbonyl compounds of Formula: (I) as described herein. Compounds as modulators of his-tone deacetylase (HDAC), pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.
Abstract translation: 本文公开的是如本文所述的式（I）的羰基化合物。 公开了作为其脱色酶脱乙酰酶（HDAC）调节剂的化合物，包含其的药物组合物和使用其的治疗疾病的方法。
-
Patent Agency Ranking
公开(公告)号：US07087601B2
公开(公告)日：2006-08-08
申请号：US10497452
申请日：2002-11-26
Applicant: Jeannie Arruda , Celine Bonnefous , Brian T. Campbell , Rowena V. Cube , Benito Munoz , Brian Stearns , Jean-Michel Vernier , Bowei Wang , Xiumin Zhao
Inventor： Jeannie Arruda , Celine Bonnefous , Brian T. Campbell , Rowena V. Cube , Benito Munoz , Brian Stearns , Jean-Michel Vernier , Bowei Wang , Xiumin Zhao
IPC: A61K31/5383 , A61K31/437 , C07D413/14 , C07D491/048
CPC classification number: C07D263/57 , C07D231/12 , C07D233/56 , C07D249/08 , C07D413/10
Abstract: Phenyl compounds substituted at the 1-position with a fused bicyclo moeity formed from a five-membered heterocycle fused to a six-membered carbocycle, to a six-membered aryl, or to a six-membered hetaryl, and further optionally substituted at the 3,4 positions, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.
Abstract translation: 苯基化合物在1-位上被一个稠合的双环自由基组成，它由与六元碳环稠合的五元杂环，六元芳基或六元杂芳基形成，并进一步任选地被取代在3位上 ，4个位置是mGluR5调节剂，可用于治疗精神病和情绪障碍，例如精神分裂症，焦虑，抑郁和恐慌，以及治疗疼痛和其他疾病。
-
公开(公告)号：US08455534B2
公开(公告)日：2013-06-04
申请号：US13613467
申请日：2012-09-13
Applicant: Nicholas D. Smith , Mehmet Kahraman , Steven P. Govek , Johnny Y. Nagasawa , Andiliy G. Lai , Jackaline D. Julien , Celine Bonnefous
Inventor： Nicholas D. Smith , Mehmet Kahraman , Steven P. Govek , Johnny Y. Nagasawa , Andiliy G. Lai , Jackaline D. Julien , Celine Bonnefous
IPC: A61K31/416 , C07D231/56
CPC classification number: C07D231/56 , A61K31/416 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K31/7105 , C07C215/10 , C07D209/08 , C07D215/227 , C07D217/24 , C07D249/18 , C07D265/18 , C07D277/68 , C07D279/16 , C07D401/10 , C07D401/12 , C07D403/10 , C07D409/10 , C07D413/10 , C07D417/10 , C07D471/04 , C07D495/04
Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
公开(公告)号：US20120071535A1
公开(公告)日：2012-03-22
申请号：US13234035
申请日：2011-09-15
Applicant: Nicholas D. SMITH , Mehmet KAHRAMAN , Steven P. GOVEK , Johnny Y. NAGASAWA , Andiliy G. LAI , Jackaline D. Julien , Celine Bonnefous
Inventor： Nicholas D. SMITH , Mehmet KAHRAMAN , Steven P. GOVEK , Johnny Y. NAGASAWA , Andiliy G. LAI , Jackaline D. Julien , Celine Bonnefous
IPC: A61K31/416 , A61P35/00 , A61P25/32 , A61P25/06 , A61P9/00 , A61P19/02 , A61P15/08 , A61P9/12 , A61P1/08 , A61P25/24 , A61P1/16 , A61P25/00 , A61P25/28 , A61P25/16 , A61P3/04 , A61P19/08 , A61P19/10 , C07D231/56
CPC classification number: C07D231/56 , A61K31/416 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K31/7105 , C07C215/10 , C07D209/08 , C07D215/227 , C07D217/24 , C07D249/18 , C07D265/18 , C07D277/68 , C07D279/16 , C07D401/10 , C07D401/12 , C07D403/10 , C07D409/10 , C07D413/10 , C07D417/10 , C07D471/04 , C07D495/04
Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
Abstract translation: 本文描述的是雌激素受体调节剂的化合物。 还描述了包括本文所述化合物的药物组合物和药物，以及使用这种雌激素受体调节剂单独使用并与其它化合物联合用于治疗介导或依赖于雌激素受体的疾病或病症的方法。
-
公开(公告)号：US07408067B2
公开(公告)日：2008-08-05
申请号：US10500517
申请日：2002-07-29
Applicant: Peter Charles Astles , Stephen Richard Baker , Celine Bonnefous , Jean Michel Vernier , Martine Keenan , Adam Jan Sanderson
Inventor： Peter Charles Astles , Stephen Richard Baker , Celine Bonnefous , Jean Michel Vernier , Martine Keenan , Adam Jan Sanderson
IPC: C07D211/22 , C07D401/00
CPC classification number: C07D401/06 , C07D207/12 , C07D211/54 , C07D223/06 , C07D401/12 , C07D405/06 , C07D413/12 , C07D417/06
Abstract: Compounds comprising an aza-cyclic portion and an aromatic portion linked via a sulphur atom are disclosed. The compounds disclosed are selective modulators of beta 4 subtype nicotinic acetylcholine receptors and are useful for the treatment of dysfunctions of the central and autonomic nervous systems.
Abstract translation: 公开了包含氮杂环状部分和通过硫原子连接的芳香族部分的化合物。 所公开的化合物是β4亚型烟碱乙酰胆碱受体的选择性调节剂，并且可用于治疗中枢神经系统和自主神经系统的功能障碍。
-
公开(公告)号：US09399646B2
公开(公告)日：2016-07-26
申请号：US13821190
申请日：2011-09-15
Applicant: Nicholas D. Smith , Mehmet Kahraman , Steven P. Govek , Johnny Y. Nagasawa , Andiliy G. Lai , Jackaline D. Julien , Mark R. Herbert , Celine Bonnefous , Karensa L. Douglas
Inventor： Nicholas D. Smith , Mehmet Kahraman , Steven P. Govek , Johnny Y. Nagasawa , Andiliy G. Lai , Jackaline D. Julien , Mark R. Herbert , Celine Bonnefous , Karensa L. Douglas
IPC: C07D495/04 , C07D209/08 , C07D231/56 , C07D249/18 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K31/7105 , C07D215/227 , C07D217/24 , C07D265/18 , C07D277/68 , C07D279/16 , C07D401/10 , C07D409/10 , C07D471/04 , C07D401/12 , C07D403/10 , C07D413/10 , C07D417/10
CPC classification number: C07D231/56 , A61K31/416 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K31/7105 , C07C215/10 , C07D209/08 , C07D215/227 , C07D217/24 , C07D249/18 , C07D265/18 , C07D277/68 , C07D279/16 , C07D401/10 , C07D401/12 , C07D403/10 , C07D409/10 , C07D413/10 , C07D417/10 , C07D471/04 , C07D495/04
Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
Abstract translation: 本文描述的是雌激素受体调节剂的化合物。 还描述了包括本文所述化合物的药物组合物和药物，以及使用这种雌激素受体调节剂单独和与其它化合物组合用于治疗介导或依赖于雌激素受体的疾病或病症的方法。
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.022 seconds)
